Literature DB >> 35102541

Overexpression of lncRNA IRAIN restrains the progression and Temozolomide resistance of glioma via repressing IGF-1R-PI3K-NF-κB signaling pathway.

Aishun Guo1, Guixia Fang2, Zhenrong Lin1, Shuishun Zheng1, Zhijun Zhuang1, Ruisheng Lin1, Yanling Lin3.   

Abstract

BACKGROUND: Increasing studies have found that long noncoding RNAs (lncRNAs) contribute to regulating tumor progression. This study explores the expression characteristics, effects, and related mechanisms of lncRNA IGF1R antisense imprinted non-protein coding RNA (IRAIN) in glioma.
METHODS: Quantitative real-time PCR (qRT-PCR) was implemented to testify the IRAIN profile in glioma tissues and paracancerous tissues, and the link between the IRAIN level and the clinicopathological indicators of glioma was analyzed. IRAIN overexpression and knockdown cell models were constructed in glioma cells. Cell proliferation was verified by the colony formation experiment, while flow cytometry was implemented to monitor apoptosis. Transwell assay was performed to examine cell invasion and migration. Western blot (WB) was adopted to compare the profiles of the apoptosis-related proteins (Bax, Bcl2, and Caspase3) and IGF-1R-PI3K-NF-κB pathway.
RESULTS: IRAIN was down-regulated in glioma tissues (compared with adjacent normal tissues), and the low IRAIN expression was significantly linked with the larger tumor volume and higher pathological stages. Functionally, overexpressing IRAIN abated glioma cell proliferation, invasion, and migration, promoted apoptosis, and attenuated IGF-1R-PI3K-NF-κB expression and temozolomide (TMZ) resistance, which was also confirmed in the xenograft tumor experiment. The WB result showed that overexpressing IRAIN inactivated the IGF-1R-PI3K-NF-κB pathway. Additionally, the IGF-1R knockdown model was established in U251 cells. Si-IGF-1R induced cell proliferation inhibition, promoted cell death, and reduced cell migration and TMZ resistance, whereas Si-IGF-1R+IRAIN group showed no additional effects on glioma cells compared with the Si-IGF-1R group.
CONCLUSION: IRAIN repressed glioma development and TMZ resistance by inactivating the IGF-1R-PI3K-NF-κB axis.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35102541     DOI: 10.14670/HH-18-425

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.130


  37 in total

1.  LncRNA CASC7 inhibits the progression of glioma via regulating Wnt/β-catenin signaling pathway.

Authors:  Xin Gong; Xiaoyun Liao; Mengyi Huang
Journal:  Pathol Res Pract       Date:  2019-01-14       Impact factor: 3.250

Review 2.  Origin of Gliomas.

Authors:  Daniel Cahill; Sevin Turcan
Journal:  Semin Neurol       Date:  2018-03-16       Impact factor: 3.420

3.  LncRNA CPS1-IT1 serves as anti-oncogenic role in glioma.

Authors:  Hengsan Chen; Qiang Li; Jin Liang; Ming Jin; Anqing Lu
Journal:  Biomed Pharmacother       Date:  2019-08-21       Impact factor: 6.529

Review 4.  Targeted Radiolabeled Compounds in Glioma Therapy.

Authors:  Dominik Cordier; Leszek Krolicki; Alfred Morgenstern; Adrian Merlo
Journal:  Semin Nucl Med       Date:  2016-05       Impact factor: 4.446

Review 5.  Insulin-like growth factors in the brain and their potential clinical implications.

Authors:  Eduardo E Benarroch
Journal:  Neurology       Date:  2012-11-20       Impact factor: 9.910

6.  MiR-503-5p functions as an oncogene in oral squamous cell carcinoma by targeting Smad7.

Authors:  Yifan Fei; Weilan Shan; Xiaoqing Chen
Journal:  Histol Histopathol       Date:  2020-04-22       Impact factor: 2.303

7.  LncRNA PLAC2 down-regulates RPL36 expression and blocks cell cycle progression in glioma through a mechanism involving STAT1.

Authors:  Yan-Wei Hu; Chun-Min Kang; Jing-Jing Zhao; Ying Nie; Lei Zheng; Hai-Xia Li; Xin Li; Qian Wang; Yu-Rong Qiu
Journal:  J Cell Mol Med       Date:  2017-09-18       Impact factor: 5.310

8.  Overexpression of lncRNA PTENP1 suppresses glioma cell proliferation and metastasis in vitro.

Authors:  Su Hu; Li Xu; Lihua Li; Dongdong Luo; Hailin Zhao; Dan Li; Biao Peng
Journal:  Onco Targets Ther       Date:  2018-12-21       Impact factor: 4.147

9.  LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.

Authors:  Xin He; Jie Sheng; Wei Yu; Kejian Wang; Shujuan Zhu; Qian Liu
Journal:  Cell Mol Neurobiol       Date:  2020-06-11       Impact factor: 5.046

10.  lncRNA CCAT2 Enhanced Resistance of Glioma Cells Against Chemodrugs by Disturbing the Normal Function of miR-424.

Authors:  Jun Ding; Lin Zhang; Shiwen Chen; Heli Cao; Chen Xu; Xuyang Wang
Journal:  Onco Targets Ther       Date:  2020-02-17       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.